Abstract: Compounds, compositions, and methods for the treatment or prevention of symptoms, conditions, and diseases that may benefit from NMDAR modulation, including administering a compound of the morphinan family to a subject. The method may include administration of dextromorphine to a subject experiencing a symptom, condition, or disease that may benefit from NMDAR modulation, (except for the indications of pain and addiction), or may include administering dextrocodeine, dextrohydromorphone, dextrohydrocodone, dextrooxymorphone, dextrooxycodone, dextrooripavine, dextrothebaine, dextroethorphine, and dextrobuprenorphine to a subject experiencing a symptom, condition, or disease that may benefit from NMDAR modulation. Derivatives and stereoisomers of such compounds may also be used.

Abstract: Methods and compositions for modifying the course and severity of neuropsychiatric disorders. The method includes administering a composition to a subject suffering from a neuropsychiatric disorder, wherein the composition includes a substance selected from dextromethadone, dextromethadone metabolites, d-methadol, d-alpha-acetylmethadol, d-alpha-normethadol, l-alpha-normethadol, and pharmaceutically acceptable salts thereof.

Abstract: Compositions and methods of use comprising serotonin (5-HT) receptor agonists and NMDAR modulating substances, including especially certain substances classified as 5-HT2A agonists presently disclosed to exert NMDAR modulating effects, administered as modulators of neural plasticity, at non-psychedelic/psychotomimetic dosages, posology and formulations, for treatment of diseases and conditions and for improving functions (neuroplastogens).

Abstract: Aspects of the present invention are directed to structurally modified opioids (SMOs) that result in improved modulating activity at the NMDAR and improved PK and PD parameters over existing drugs with NMDAR modulating activity. The structural modifications of an opioid or opioid enantiomer that result in the SMOs can be obtained by starting the synthetic process de novo; by modifying the synthetic process for the opioid at any intermediate step during the synthesis of the racemate or of one enantiomer; or by modifying the structure of the opioid or opioid enantiomer after the synthesis. The nitric acid ester substitutions are of particular relevance, especially when associated to deuterated substitutions and/or halogen substitutions.